Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Financings Of The Fortnight And The Never-Ending Venture Round

Feb 21 2014

• By Alex Lash, Paul Bonanos, Stacy Lawrence, and Maureen Riordan

Related Content

Does Alnylam Lift All Oligo Boats? The Dicerna IPO

Feb 14 2014

How And Why Genzyme And Alnylam Expanded Their Alliance

Feb 14 2014

Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics

Oct 07 2013

Related Companies

Bristol Myers Squibb Company

Light Chain Bioscience

Sangart Inc.

Symphogen A/S

Theraclone Sciences, Inc.

Endocyte, Inc.

Alvine Pharmaceuticals, Inc.

AbbVie Inc.

Genentech, Inc.

Melinta Therapeutics, Inc.

Argos Therapeutics, Inc.

Arrowhead Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

MacroGenics, Inc.

PTC Therapeutics, Inc.

Puma Biotechnology, Inc.

Alnylam Pharmaceuticals Inc.

Sanofi

Sanofi Genzyme

Dicerna Pharmaceuticals, Inc.

Axcella Therapeutics, Inc.

Additional Topics

United States Business Strategies Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window